Hypothyroidism during treatment with tyrosine kinase inhibitors

Endokrynologia Polska

Volumn 63, Issue 4, 2012, Pages 302-306

  Zygulska, Aneta L ^a   Krzemieniecki, Krzysztof ^a   Sowa Staszczak, Anna ^a  

^a UNIVERSITY HOSPITAL IN KRAKOW   (Poland)

Author keywords

Hypothyroidism; Tyrosine kinase inhibitors

Indexed keywords

IMATINIB; LIOTHYRONINE; MOTESANIB; SODIUM IODIDE SYMPORTER; SORAFENIB; SUNITINIB; THYROID HORMONE; THYROID PEROXIDASE; THYROTROPIN; THYROTROPIN RECEPTOR; THYROXINE; VASCULOTROPIN RECEPTOR;

ANOREXIA; CANCER GROWTH; CHRONIC MYELOID LEUKEMIA; DERMATOFIBROSARCOMA PROTUBERANS; DIFFERENTIATED THYROID CANCER; DRUG EFFICACY; FATIGUE; FLUID RETENTION; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HYPOTHYROIDISM; KIDNEY CARCINOMA; KIDNEY METASTASIS; LYMPHOCYTIC THYROIDITIS; MULTIPLE CYCLE TREATMENT; PANCREATIC NEUROENDOCRINE TUMOR; REVIEW; SIDE EFFECT; SOLID TUMOR; THYROID FUNCTION; THYROID HORMONE SYNTHESIS; THYROID MEDULLARY CARCINOMA; THYROIDITIS; THYROTOXICOSIS; TRACHEOTOMY; TREATMENT DURATION; TREATMENT RESPONSE;

CARCINOMA, RENAL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTROINTESTINAL NEOPLASMS; HUMANS; INDOLES; KIDNEY NEOPLASMS; LIVER NEOPLASMS; NEOPLASM METASTASIS; NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PYRROLES; THYROID DISEASES; THYROID FUNCTION TESTS; THYROID GLAND; THYROID NEOPLASMS;

EID: 84865983926     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Illouz F, Laboureau-Soares S, Dubois S et al. Tyrosine kinase inhibitors and modifications of thyroid function tests: a review. Eur J Endocrin 2009; 160: 331-336.
2. Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009; 10: 470-481.
3. Rios MB, Ault P. Identification of side effects associated with intolerance to BCR-ABL inhibitors in patients with chronic myeloid leukemia. Clin J Oncol Nurs 2011; 15: 660-667.
4. Salem AK, Fenton MS, Marion KM, Hershman JM. Effect of sunitinib on growth and function of FRTL-5 thyroid cells. Thyroid 2008; 18: 631-635. (Pubitemid 351918450)
5. Chan JA, Kulke MH. New treatment options for patients with advanced neuroendocrine tumors. Curr Treat Options Oncol 2011; 12: 136-148.
6. Dong M, Phan AT, Yao JC. New strategies for advanced neuroendocrine tumors in the era of targeted therapy. Clin Cancer Res 2012; 18: 1830-1836.
7. Desai J, Yassa L, Marquesse E et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006; 145: 660-664. (Pubitemid 46768841)
8. Mannavola D, Coco P, Vannucchi G et al. A novel-tyrosine kinase inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. JCEM 2007; 92: 3531-3534. (Pubitemid 47435331)
9. Rini BI, Tamaskar I, Shaheen P et al. Hypothyroidism in patients with metastatic renal carcinoma treated with sunitinib. JNCI 2007; 99: 81-83.
10. Wong E, Rosen LS, Mulay M A et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 2007; 17: 351-355.
11. Vetter ML, Kaul S, Iqbal N. Tyrosine kinase inhibitors and the tyroid as both an unintended and an intended target. Endocr Pract 2008; 14: 618-624.
12. Kollmannsberger C, Soulieres D, Wong R et al. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. CUAJ 2007; 1 (Suppl 2): 41-54.
13. Sato S, Muraishi K, Tani J et al. Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma. Endocrin J 2010; 57: 873-880.
14. de Groot JW, Zonnenberg BA, Quarles van Ufford-Mannesse P et al. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. JCEM 2007; 92: 3466-3469. (Pubitemid 47435321)
15. Grossman M, Premaratne E, Desai J, Davis ID. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf) 2008; 69: 669-672.
16. Wolter P, Stefan C, Decallone B et al. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer 2008; 99: 448-454.
17. Sakurai K, Fukazawa H, Arihara Z, Yoshida K. Sunitinib-induced thyrotoxicosis followed by persistent hypothyroidism with shrinkage of thyroid volume. Tohoku J Exp Med 2010; 222: 39-44.
18. Rogiers A, Wolter P, Op de Beeck K et al. Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction? Thyroid 2010; 20: 317-322.
19. Makita N, Miyakawa M, Fujita T, Iiri T. Sunitinib induces hypothyroidism with a markedly reduced vascularity. Thyroid 2010; 20: 323-326.
20. Baffert F, Le T, Sennino B, Thurston G et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol 2006; 290: H547-H559.
21. Alexandrescu DT, Popoveniuc G, Farzanmehr H et al. Sunitinib associated lymphocytic thyroiditis without circulating antithyroid antibodies. Thyroid 2008; 18: 809-812. (Pubitemid 352009925)
22. Schmidinger M, Vogl UM, Bojic M et al. Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer 2011; 117: 534-544.
23. Tamaskar I, Bukowski R, Elson P, Ioachimescu AG. Thyroid function test abnormalities in patients with metastatic renal cell cacinoma treated with sorafenib. Ann Oncol 2008; 19: 265-268. (Pubitemid 351201706)
24. Abdulrahman RM, Verloop H, Hoftijzer H et al. Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. J Clin Endocrinol Metab 2010; 95: 3758-3762.
25. Gupta-Abramson V, Troxel AB, Nellore A et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008; 26: 4714-4719.
26. Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 2009; 6: 219-228.
27. Dora JM, Leie MA, Netto B et al. Lack of imatinib-induced thyroid dysfunction in a cohort of non-thyroidectomized patients. Letter to editor. Eur J Encodcrin 2008; 158: 771-772. (Pubitemid 351639617)
28. de Groot JW, Zonnenberg BA, Plukker JT, van Der Graaf WT, Links TP. Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther 2005; 78: 433-438. (Pubitemid 41393678)
29. Rosen LS, Kurzrock R, Mulay M et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. JCO 2007; 25: 2369-2376. (Pubitemid 46999207)
30. Schlumberger MJ, Elisei R, Bastholt L et al. Phase II study of safety and efficacy of motesanib in patients with progressive, symptomatic, advanced or metastatic medullary thyroid cancer. JCO 2009; 27: 3794-3801.
31. Sherman SI, Wirth LJ, Droz JP et al. Motesanib diphosphate in progressive differentiated thyroid cancer. NEJM 2008; 359: 31-42. (Pubitemid 351931094)